Attana receives follow up contract research order from HVD Life Sciences
Attana has received a follow up contract research order from distribution partner HVD Life Sciences. The contract concerns more detailed characterization of antibody-antigen interactions compared with the first order. The experiments will be performed during Q4.
In March, Attana and HVD Life Sciences signed a distribution agreement covering Asia, Russia including CIS/NIS, Eastern Europe, South East Europe and Austria. The current order is an extension of the previous announced order from September 5th from an customer within HVD Life Sciences territory. Attana’s application specialists will perform interaction analysis assays in different crude media. The results will be used for target detection applications in crude environments where proteins and other biomolecules makes detection difficult.
To learn more about the agreement with HVD Life Sciences, please read previous communication.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release does not affect the share price, but is of general interest for the share holders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
